Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia |
| |
| Authors: | Stuart A. Ross A. Enrique Caballero Stefano Del Prato Baptist Gallwitz Diane Lewis-D’Agostino Zelie Bailes |
| |
| Affiliation: | 1. LMC Endocrinology Centres, University of Calgary, Calgary, Canadadrross@telus.net;3. Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA;4. Department of Endocrinology and Metabolism, Section of Diabetes, University of Pisa, Pisa, Italy;5. Department of Medicine IV, Universit?tsklinikum Tübingen, Tübingen, Germany;6. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA;7. Boehringer Ingelheim Ltd, Bracknell, UK |
| |
| Abstract: | Objectives: Few studies of oral glucose-lowering drugs exist in newly diagnosed type 2 diabetes (T2D) patients with marked hyperglycemia, and insulin is often proposed as initial treatment. We evaluated the oral initial combination of metformin and linagliptin, a dipeptidyl peptidase-4 inhibitor, in this population.Methods: We performed a pre-specified subgroup analysis of a randomized study in which newly diagnosed T2D patients with glycated hemoglobin A1c (HbA1c) 8.5%–12.0% received linagliptin/metformin or linagliptin monotherapy. Subgroups of baseline HbA1c, age, body-mass index (BMI), renal function, race, and ethnicity were evaluated, with efficacy measured by HbA1c change from baseline after 24 weeks.Results: HbA1c reductions from baseline (mean 9.7%) at week 24 in the overall population were an adjusted mean ?2.81% ± 0.12% with linagliptin/metformin (n = 132) and ?2.02% ± 0.13% with linagliptin (n = 113); treatment difference ?0.79% (95% CI ?1.13 to ?0.46, P < 0.0001). In patients with baseline HbA1c ≥9.5%, HbA1c reduction was ?3.37% with linagliptin/metformin (n = 76) and ?2.53% with linagliptin (n = 61); difference ?0.84% (95% CI ?1.32 to ?0.35). In those with baseline HbA1c <9.5%, HbA1c reduction was ?2.08% with linagliptin/metformin (n = 56) and ?1.39% with linagliptin (n = 52); difference ?0.69% (95% CI ?1.23 to ?0.15). Changes in HbA1c and treatment differences between the linagliptin/metformin and linagliptin groups were of similar magnitudes to the overall population across patient subgroups based on age, BMI, renal function, and race. Drug-related adverse events occurred in 8.8% and 5.7% of linagliptin/metformin and linagliptin patients, respectively; no severe hypoglycemia occurred.Conclusion: Linagliptin/metformin combination in newly diagnosed T2D patients with marked hyperglycemia was well tolerated and elicited substantial improvements in glycemic control regardless of baseline HbA1c, age, BMI, renal function, or race. Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents.Clinical trial registration: www.clinicaltrials.gov identifier is NCT01512979 |
| |
| Keywords: | Diabetes mellitus type 2 drug therapy combination metformin dipeptidyl peptidase 4 inhibitors linagliptin clinical trial |
|
|
